1. Home
  2. RGNX

as of 12-15-2025 10:08am EST

$14.78
+$0.88
+6.36%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Chart Type:
Time Range:
Founded: 2008 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 661.2M IPO Year: 2015
Target Price: $30.29 AVG Volume (30 days): 626.9K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.46 EPS Growth: N/A
52 Week Low/High: $5.04 - $14.24 Next Earning Date: 11-06-2025
Revenue: $161,318,000 Revenue Growth: 91.30%
Revenue Growth (this year): 132.8% Revenue Growth (next year): 48.47%

AI-Powered RGNX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 70.20%
70.20%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of REGENXBIO Inc. (RGNX)

Simpson Curran

Chief Executive Officer

Sell
RGNX Sep 29, 2025

Avg Cost/Share

$10.03

Shares

7,624

Total Value

$76,468.72

Owned After

236,973

SEC Form 4

Share on Social Networks: